Early phase trials have reportedoverall response rates (ORRs) of 7 and 22%, for these agents as monotherapy inrelapsed mCRC, respectively.50,51 The phase III KRYSTAL-10study evaluating adagrasib plus cetuximab versus chemotherapyin patients with relapsed advanced CRC and KRAS G12C mutationsis ongoing.52 The gene discussed is KRAS; the disease is colorectal carcinoma.